The tally of infections tied to an explosive diarrhea-causing parasite that's spreading across the U.S. just jumped again.
The bottleneck isn’t the math. It’s the execution. And execution can't be delegated to an innovation committee.
How do environmental journalists convince the public that climate change really is an existential crisis? As the former BBC ...
A new analysis of Indeed job postings suggests that familiarity with AI isn't just in demand in tech.
Do hydration breaks really make a difference, or are they simply a brief pause in play and a convenient opportunity for ...
We saw this with both Allen and Daws in the past couple of years. I’ve said a bunch lately that Nico Daws and Jake Allen ...
US oil prices have tumbled nearly 40% since May, but technical analysis suggests a potential for another price surge due to ...
Vulcan Materials stock is a "Buy" given its geographic moat and pricing power to drive robust growth. Here's what you need to ...
Carbon Brief explains why AC rates in parts of Europe are relatively low and clarifies some of the misleading claims about ...
Sky Quarry Taps 35-Year Refining Veteran to Run Foreland as Nevada's Only Refinery Enters Production
Former HF Sinclair, CITGO and Chevron leader Ray Hansen steps in as President of Foreland Refining just as the Eagle Springs refinery near Ely ...
How Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go? eToro Group (NASDAQ:ETOR) unveiled a broad set of AI-focused ...
32mon MSN
AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results